|
JP4341949B2
(ja)
|
2000-09-01 |
2009-10-14 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
アザ複素環式誘導体およびその治療的使用
|
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
|
PL211125B1
(pl)
*
|
2000-09-11 |
2012-04-30 |
Novartis Vaccines & Diagnostic |
Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
|
|
US7642278B2
(en)
*
|
2001-07-03 |
2010-01-05 |
Novartis Vaccines And Diagnostics, Inc. |
Indazole benzimidazole compounds
|
|
WO2003004488A1
(en)
*
|
2001-07-03 |
2003-01-16 |
Chiron Corporation |
Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
|
|
WO2003045929A1
(en)
*
|
2001-11-26 |
2003-06-05 |
Takeda Chemical Industries, Ltd. |
Bicyclic derivative, process for producing the same, and use
|
|
US6822097B1
(en)
*
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
|
MXPA04012440A
(es)
*
|
2002-06-12 |
2005-04-28 |
Abbott Lab |
Antagonistas de receptor de hormona concentradora de melanina.
|
|
DE10238002A1
(de)
*
|
2002-08-20 |
2004-03-04 |
Merck Patent Gmbh |
Benzimidazolderivate
|
|
US20050256157A1
(en)
*
|
2002-08-23 |
2005-11-17 |
Chiron Corporation |
Combination therapy with CHK1 inhibitors
|
|
US7825132B2
(en)
*
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
|
CN100526312C
(zh)
*
|
2002-08-23 |
2009-08-12 |
诺华疫苗和诊断公司 |
苯并咪唑喹啉酮及其应用
|
|
KR20050037585A
(ko)
*
|
2002-08-23 |
2005-04-22 |
카이론 코포레이션 |
벤지미다졸 퀴놀리논 및 그들의 사용
|
|
AU2003275282A1
(en)
*
|
2002-09-30 |
2004-04-23 |
Bristol-Myers Squibb Company |
Novel tyrosine kinase inhibitors
|
|
CN100377709C
(zh)
*
|
2002-11-13 |
2008-04-02 |
希龙公司 |
受体酪氨酸激酶抑制剂的制药用途及相关检测方法
|
|
CA2501932C
(en)
*
|
2002-11-13 |
2014-03-11 |
Chiron Corporation |
Use of benzimidazole quinolinones for treating cancer
|
|
EP1590339A4
(en)
*
|
2003-01-28 |
2007-07-25 |
Smithkline Beecham Corp |
CHEMICAL COMPOUNDS
|
|
WO2004087153A2
(en)
*
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
US7627675B2
(en)
*
|
2003-05-01 |
2009-12-01 |
Cisco Technology, Inc. |
Methods and devices for regulating traffic on a network
|
|
WO2005009967A2
(en)
*
|
2003-07-22 |
2005-02-03 |
Janssen Pharmaceutica, N.V. |
Quinolinone derivatives as inhibitors of c-fms kinase
|
|
AU2004259012C1
(en)
|
2003-07-23 |
2012-08-02 |
Exelixis, Inc. |
Anaplastic lymphoma kinase modulators and methods of use
|
|
CN1976706B
(zh)
*
|
2003-11-07 |
2012-01-18 |
诺华疫苗和诊断公司 |
抑制fgfr3及治疗多发性骨髓瘤
|
|
KR101224410B1
(ko)
*
|
2003-11-07 |
2013-01-23 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
퀴놀리논 화합물을 합성하는 방법
|
|
EP1684762A4
(en)
*
|
2003-11-13 |
2009-06-17 |
Ambit Biosciences Corp |
UREA DERIVATIVES AS MODULATORS OF KINASE
|
|
WO2005053692A1
(en)
*
|
2003-12-01 |
2005-06-16 |
The Scripps Research Institute |
Advanced quinolinone based protein kinase inhibitors
|
|
AU2005216904B2
(en)
*
|
2004-02-20 |
2010-11-25 |
Novartis Vaccines And Diagnostics, Inc. |
Modulation of inflammatory and metastatic processes
|
|
GB0420722D0
(en)
|
2004-09-17 |
2004-10-20 |
Addex Pharmaceuticals Sa |
Novel allosteric modulators
|
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
US7759342B2
(en)
|
2005-01-13 |
2010-07-20 |
Signal Pharmaceuticals, Llc |
Methods of treatment and prevention using haloaryl substituted aminopurines
|
|
US7521446B2
(en)
|
2005-01-13 |
2009-04-21 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
|
WO2006081445A2
(en)
*
|
2005-01-27 |
2006-08-03 |
Novartis Vaccines And Diagnostics Inc. |
Treatment of metastasized tumors
|
|
US7534796B2
(en)
|
2005-02-18 |
2009-05-19 |
Wyeth |
Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
US7538113B2
(en)
|
2005-02-18 |
2009-05-26 |
Wyeth |
4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
DK1858919T3
(da)
|
2005-02-18 |
2012-07-16 |
Novartis Vaccines & Diagnostic |
Immunogener fra uropathogen Escherichia coli
|
|
SI2351772T1
(sl)
|
2005-02-18 |
2016-11-30 |
Glaxosmithkline Biologicals Sa |
Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
|
|
US7582634B2
(en)
|
2005-02-18 |
2009-09-01 |
Wyeth |
7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
|
|
AU2006247803B2
(en)
*
|
2005-05-13 |
2011-12-22 |
Novartis Ag |
Methods for treating drug resistant cancer
|
|
EP2465857B1
(en)
*
|
2005-05-17 |
2014-06-04 |
Novartis AG |
Methods for synthesizing heterocyclic compounds
|
|
US7531542B2
(en)
|
2005-05-18 |
2009-05-12 |
Wyeth |
Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
|
|
EP1904480A2
(en)
|
2005-05-23 |
2008-04-02 |
Novartis Pharma AG |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
|
US7582636B2
(en)
|
2005-05-26 |
2009-09-01 |
Wyeth |
Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
|
|
WO2007011777A2
(en)
|
2005-07-18 |
2007-01-25 |
Novartis Ag |
Small animal model for hcv replication
|
|
KR20080055914A
(ko)
*
|
2005-10-14 |
2008-06-19 |
에프. 호프만-라 로슈 아게 |
5-(2-클로로페닐)-1,2-디히드로-7-플루오로-8-메톡시-3-메틸-피라졸로[3,4-ｂ][1,4] 벤조디아제핀의 투여 섭생
|
|
CN102755645A
(zh)
|
2005-11-04 |
2012-10-31 |
诺华疫苗和诊断有限公司 |
佐剂配制的包含细胞因子诱导剂的流感疫苗
|
|
EP1951302A2
(en)
|
2005-11-04 |
2008-08-06 |
Novartis Vaccines and Diagnostics S.r.l. |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
|
EP1945252B1
(en)
|
2005-11-04 |
2013-05-29 |
Novartis Vaccines and Diagnostics S.r.l. |
Vaccines comprising purified surface antigens prepared from influenza viruses grown in cell culture, adjuvanted with squalene
|
|
NZ568211A
(en)
|
2005-11-04 |
2011-11-25 |
Novartis Vaccines & Diagnostic |
Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
|
|
DE102005054904A1
(de)
*
|
2005-11-17 |
2007-05-24 |
Wacker Polymer Systems Gmbh & Co. Kg |
Verfahren zur Herstellung polyvinylalkoholstabilisierter Latices
|
|
RU2433826C2
(ru)
|
2005-11-29 |
2011-11-20 |
Новартис Аг |
Композиции хинолинонов
|
|
CN101326292A
(zh)
|
2005-12-08 |
2008-12-17 |
诺瓦提斯公司 |
Fgfr3抑制物对基因转录的影响
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
JP6087041B2
(ja)
|
2006-01-27 |
2017-03-08 |
ノバルティス アーゲー |
血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン
|
|
PE20070978A1
(es)
*
|
2006-02-14 |
2007-11-15 |
Novartis Ag |
COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
|
|
TW200803855A
(en)
*
|
2006-02-24 |
2008-01-16 |
Kalypsys Inc |
Quinolones useful as inducible nitric oxide synthase inhibitors
|
|
TWI417095B
(zh)
|
2006-03-15 |
2013-12-01 |
Janssen Pharmaceuticals Inc |
１，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
|
|
CA2647100A1
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Methods for the preparation of imidazole-containing compounds
|
|
WO2007109812A2
(en)
*
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Immunopotentiating compounds
|
|
ATE539079T1
(de)
*
|
2006-03-23 |
2012-01-15 |
Novartis Ag |
Imidazochinoxalinverbindungen als immunmodulatoren
|
|
US20100068223A1
(en)
|
2006-03-24 |
2010-03-18 |
Hanno Scheffczik |
Storage of Influenza Vaccines Without Refrigeration
|
|
WO2007126825A2
(en)
|
2006-03-31 |
2007-11-08 |
Novartis Ag |
Combined mucosal and parenteral immunization against hiv
|
|
TW200808739A
(en)
*
|
2006-04-06 |
2008-02-16 |
Novartis Vaccines & Diagnostic |
Quinazolines for PDK1 inhibition
|
|
KR20080110912A
(ko)
|
2006-04-19 |
2008-12-19 |
노파르티스 아게 |
인다졸 화합물 및 ｃｄｃ７의 억제 방법
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
CA2657093A1
(en)
|
2006-07-07 |
2008-01-10 |
Steven P. Govek |
Bicyclic heteroaryl inhibitors of pde4
|
|
US8138205B2
(en)
|
2006-07-07 |
2012-03-20 |
Kalypsys, Inc. |
Heteroarylalkoxy-substituted quinolone inhibitors of PDE4
|
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
|
US20100166788A1
(en)
|
2006-08-16 |
2010-07-01 |
Novartis Vaccines And Diagnostics |
Immunogens from uropathogenic escherichia coli
|
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
|
EP2073803B1
(en)
|
2006-10-12 |
2018-09-19 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
US8883790B2
(en)
|
2006-10-12 |
2014-11-11 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
ES2480491T3
(es)
|
2006-12-06 |
2014-07-28 |
Novartis Ag |
Vacunas incluyendo antígeno de cuatro cepas de virus de la gripe
|
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
|
TW200845978A
(en)
|
2007-03-07 |
2008-12-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
|
|
TW200900065A
(en)
|
2007-03-07 |
2009-01-01 |
Janssen Pharmaceutica Nv |
3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
|
|
WO2008124323A1
(en)
*
|
2007-04-03 |
2008-10-16 |
Array Biopharma Inc. |
Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
|
|
CA2685888A1
(en)
*
|
2007-05-09 |
2008-11-20 |
Pfizer Inc. |
Substituted heterocyclic derivatives and their pharmaceutical use and compositions
|
|
EA201070066A1
(ru)
|
2007-06-27 |
2010-06-30 |
Новартис Аг |
Вакцины против гриппа с низким содержанием добавок
|
|
GB0713880D0
(en)
*
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
TWI475995B
(zh)
|
2007-09-14 |
2015-03-11 |
Janssen Pharmaceuticals Inc |
１’，３’－二取代－４－苯基－３，４，５，６－四氫－２ｈ，１’ｈ－〔１，４’〕聯吡啶基－２’－酮化物
|
|
ATE516272T1
(de)
|
2007-09-14 |
2011-07-15 |
Ortho Mcneil Janssen Pharm |
1,3-disubstituierte 4-(aryl-x-phenyl)-1h-pyridin- 2-one
|
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
|
EA201000947A1
(ru)
|
2007-12-20 |
2011-02-28 |
Новартис Аг |
Производные тиазола, применимые в качестве ингибиторов киназы pi3
|
|
EP2268309B1
(en)
|
2008-03-18 |
2015-01-21 |
Novartis AG |
Improvements in preparation of influenza virus vaccine antigens
|
|
PE20091628A1
(es)
*
|
2008-03-19 |
2009-11-19 |
Novartis Ag |
Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
|
|
EP2344470B1
(en)
|
2008-09-02 |
2013-11-06 |
Janssen Pharmaceuticals, Inc. |
3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
|
|
US8691813B2
(en)
|
2008-11-28 |
2014-04-08 |
Janssen Pharmaceuticals, Inc. |
Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
|
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
|
WO2010119343A2
(en)
|
2009-04-14 |
2010-10-21 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
|
CA2763816A1
(en)
|
2009-04-27 |
2010-11-04 |
Novartis Ag |
Adjuvanted vaccines for protecting against influenza
|
|
US8492374B2
(en)
|
2009-04-29 |
2013-07-23 |
Industrial Technology Research Institute |
Azaazulene compounds
|
|
AR078411A1
(es)
|
2009-05-07 |
2011-11-09 |
Lilly Co Eli |
Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende
|
|
MY153913A
(en)
|
2009-05-12 |
2015-04-15 |
Janssen Pharmaceuticals Inc |
7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
|
|
ES2440001T3
(es)
|
2009-05-12 |
2014-01-27 |
Janssen Pharmaceuticals, Inc. |
Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
|
|
CN102439015B
(zh)
|
2009-05-12 |
2015-05-13 |
杨森制药有限公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途
|
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
|
SG177533A1
(en)
|
2009-07-07 |
2012-02-28 |
Novartis Ag |
Conserved escherichia coli immunogens
|
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
|
PT2464658E
(pt)
|
2009-07-16 |
2015-01-14 |
Novartis Ag |
Imunogénios de escherichia coli desintoxicados
|
|
WO2011033588A1
(ja)
*
|
2009-09-18 |
2011-03-24 |
株式会社アドバンテスト |
試験装置および試験方法
|
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
|
JP2013514986A
(ja)
|
2009-12-18 |
2013-05-02 |
ノバルティス アーゲー |
血液癌の処置方法
|
|
JP5781542B2
(ja)
|
2009-12-30 |
2015-09-24 |
ノバルティス アーゲー |
Ｅ．ｃｏｌｉキャリアタンパク質に結合体化した多糖免疫原
|
|
RU2012148710A
(ru)
|
2010-04-16 |
2014-05-27 |
Новартис Аг |
Органическое соединение для применения при лечении рака печени
|
|
MX2012012058A
(es)
|
2010-04-16 |
2012-11-22 |
Novartis Ag |
Combinacion de compuestos organicos.
|
|
KR20130121699A
(ko)
|
2010-05-28 |
2013-11-06 |
테트리스 온라인, 인코포레이티드 |
상호작용 혼성 비동기 컴퓨터 게임 기반구조
|
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
|
AR081776A1
(es)
|
2010-06-30 |
2012-10-17 |
Novartis Ag |
Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
|
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
|
AR082418A1
(es)
|
2010-08-02 |
2012-12-05 |
Novartis Ag |
Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
|
|
AU2011297961B2
(en)
|
2010-09-02 |
2015-07-02 |
Merck Patent Gmbh |
Pyrazolopyridinone derivatives as LPA receptor antagonists
|
|
JO3062B1
(ar)
*
|
2010-10-05 |
2017-03-15 |
Lilly Co Eli |
R)-(e)-2-(4-(2-(5-(1-(3، 5-داي كلورو بيريدين-4-يل)إيثوكسي)-1h-إندازول-3-يل)?ينيل)-1h-بيرازول-1-يل)إيثانول بلوري
|
|
WO2012062751A1
(en)
|
2010-11-08 |
2012-05-18 |
Janssen Pharmaceuticals, Inc. |
1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
|
|
CN103298810B
(zh)
|
2010-11-08 |
2016-03-16 |
杨森制药公司 |
1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
|
|
US8993591B2
(en)
|
2010-11-08 |
2015-03-31 |
Janssen Pharmaceuticals, Inc. |
1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
|
|
WO2012103361A1
(en)
|
2011-01-26 |
2012-08-02 |
Novartis Ag |
Rsv immunization regimen
|
|
US8987257B2
(en)
|
2011-01-31 |
2015-03-24 |
Novartis Ag |
Heterocyclic derivatives
|
|
US20130345234A1
(en)
|
2011-03-17 |
2013-12-26 |
Humphrey Athelstan Roy Gardner |
Fgfr and ligands thereof as biomarkers for breast cancer in hr positive subjects
|
|
SI2707385T1
(en)
|
2011-05-13 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Pregnant RSV F antigens
|
|
JP2014515353A
(ja)
|
2011-05-19 |
2014-06-30 |
ノバルティス アーゲー |
腺様嚢胞癌の治療に使用するための４−アミノ−５−フルオロ−３−［６−（４−メチルピペラジン−１−イル）−１ｈ−ベンゾイミダゾール−２−イル］−１ｈ−キノリン−２−オン
|
|
EP2554662A1
(en)
|
2011-08-05 |
2013-02-06 |
M Maria Pia Cosma |
Methods of treatment of retinal degeneration diseases
|
|
MX2014003182A
(es)
|
2011-09-15 |
2014-09-22 |
Novartis Ag |
Uso de 4-amino-5-fluoro-3-[6-(4-metilpiperazin-1-il)-1h-bencimidaz ol-2-il]-1h-quinolin-2-ona en el tratamiento de cancer en pacientes con insuficiencia hepática moderada.
|
|
KR20140090218A
(ko)
|
2011-10-28 |
2014-07-16 |
노파르티스 아게 |
신규 퓨린 유도체 및 질환의 치료에서의 그의 용도
|
|
WO2013063003A1
(en)
|
2011-10-28 |
2013-05-02 |
Novartis Ag |
Method of treating gastrointestinal stromal tumors
|
|
AU2012335208B2
(en)
|
2011-11-07 |
2017-08-31 |
Glaxosmithkline Biologicals S.A. |
Carrier molecule comprising a spr0096 and a spr2021 antigen
|
|
WO2013116293A1
(en)
|
2012-01-31 |
2013-08-08 |
Novartis Ag |
Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
|
|
HK1202435A1
(en)
|
2012-05-16 |
2015-10-02 |
Novartis Ag |
Dosage regimen for a pi-3 kinase inhibitor
|
|
BR112015000349A2
(pt)
|
2012-07-11 |
2017-06-27 |
Novartis Ag |
método de tratamento de tumores estromais gastrointestinais
|
|
BR112015007126A2
(pt)
|
2012-10-02 |
2017-08-08 |
Glaxosmithkline Biologicals Sa |
composição, método para induzir uma resposta imune, e, uso de uma composição
|
|
WO2014058785A1
(en)
|
2012-10-10 |
2014-04-17 |
Novartis Ag |
Combination therapy
|
|
CN103804353A
(zh)
*
|
2012-11-01 |
2014-05-21 |
常辉 |
一类治疗精神分裂症的化合物及其用途
|
|
HRP20180039T1
(hr)
|
2012-11-30 |
2018-04-06 |
Glaxosmithkline Biologicals S.A. |
Antigeni pseudomonasa i kombinacije antigena
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
EP2956138B1
(en)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
|
ES2831625T3
(es)
|
2013-02-20 |
2021-06-09 |
Kala Pharmaceuticals Inc |
Compuestos terapéuticos y sus usos
|
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
|
WO2014191938A1
(en)
|
2013-05-31 |
2014-12-04 |
Novartis Ag |
Combination therapy containing a pi3k-alpha inhibitor and fgfr kinase inhibitor for treating cancer
|
|
JO3368B1
(ar)
|
2013-06-04 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
|
|
JO3367B1
(ar)
|
2013-09-06 |
2019-03-13 |
Janssen Pharmaceutica Nv |
مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
|
|
AU2014334554B2
(en)
|
2013-10-14 |
2018-12-06 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
|
BR112016008378B1
(pt)
|
2013-10-14 |
2022-11-08 |
Eisai R&D Management Co., Ltd |
Compostos de quinolina seletivamente substituídos ou sal dos mesmos, e composição farmacêutica contendo os ditos compostos
|
|
CN108530458A
(zh)
|
2013-11-01 |
2018-09-14 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
|
MX378409B
(es)
|
2013-12-06 |
2025-03-10 |
Novartis Ag |
Regimen de dosificacion para un inhibidor selectivo alfa-isomorfo de fosfatidilinositol 3-quinasa.
|
|
EP3424535A1
(en)
|
2014-01-21 |
2019-01-09 |
Janssen Pharmaceutica NV |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
|
PH12019500127B1
(en)
|
2014-01-21 |
2022-05-04 |
Janssen Pharmaceutica Nv |
Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
|
|
US20170165230A1
(en)
|
2014-04-09 |
2017-06-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
EA201790010A1
(ru)
|
2014-07-09 |
2017-05-31 |
ТиСи БАЙОФАРМ ЛТД. |
Гамма-дельта t-клетки и их применение
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
KR101693781B1
(ko)
*
|
2014-10-06 |
2017-01-09 |
한양대학교 에리카산학협력단 |
다이플루오로알킬기가 도입된 방향족 화합물의 제조 방법
|
|
US20170304313A1
(en)
|
2014-10-06 |
2017-10-26 |
Novartis Ag |
Therapeutic Combination For The Treatment Of Cancer
|
|
CN104774221B
(zh)
*
|
2015-03-19 |
2017-02-08 |
广西师范大学 |
喹啉酮衍生物的金属配合物及其合成方法及应用
|
|
CN104817535A
(zh)
*
|
2015-03-19 |
2015-08-05 |
广西师范大学 |
一种喹啉酮衍生物及其合成方法及应用
|
|
CN104725431B
(zh)
*
|
2015-03-19 |
2017-05-17 |
广西师范大学 |
喹啉酮衍生物的钴(ⅱ)配合物及其合成方法及应用
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
US10519133B2
(en)
|
2015-08-07 |
2019-12-31 |
Medshine Discovery Inc. |
Vinyl compounds as FGFR and VEGFR inhibitors
|
|
AR105911A1
(es)
|
2015-09-03 |
2017-11-22 |
Forma Therapeutics Inc |
Inhibidores de hdac8 bicíclicos fusionados [6,6]
|
|
AU2016331955B2
(en)
|
2015-09-30 |
2022-07-21 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
|
|
WO2017077445A1
(en)
|
2015-11-02 |
2017-05-11 |
Novartis Ag |
Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
|
|
EP3231434A1
(en)
|
2016-04-14 |
2017-10-18 |
Fundacio Centre de Regulacio Genomica |
Method of treatment of parkinsonism
|
|
EP3509421A4
(en)
|
2016-09-08 |
2020-05-20 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
|
EP3509423A4
(en)
|
2016-09-08 |
2020-05-13 |
Kala Pharmaceuticals, Inc. |
CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
|
|
WO2018060833A1
(en)
|
2016-09-27 |
2018-04-05 |
Novartis Ag |
Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
|
|
CN107935858B
(zh)
*
|
2016-10-12 |
2020-09-08 |
利尔化学股份有限公司 |
5-氟-2-硝基苯酚的制备方法
|
|
EP3645526B1
(en)
|
2017-06-27 |
2024-09-04 |
Janssen Pharmaceutica NV |
New quinolinone compounds
|
|
WO2019101182A1
(en)
|
2017-11-24 |
2019-05-31 |
Janssen Pharmaceutica Nv |
Pyrazolopyridinone compounds
|
|
BR112020010004A2
(pt)
|
2017-11-24 |
2020-10-13 |
Janssen Pharmaceutica Nv |
compostos de pirazolopiridinona
|
|
CN111448185A
(zh)
|
2017-12-07 |
2020-07-24 |
哈尔滨珍宝制药有限公司 |
一种作为fgfr和vegfr抑制剂化合物的盐型、晶型及其制备方法
|
|
CN109553534A
(zh)
*
|
2018-11-27 |
2019-04-02 |
常州大学 |
一种2-硝基-4-甲氧基苯甲酸的制备方法
|
|
CA3123699A1
(en)
|
2018-12-26 |
2020-07-02 |
Janssen Pharmaceutica Nv |
Thienopyridinone compounds
|
|
US10835531B1
(en)
|
2019-06-18 |
2020-11-17 |
Oncology Venture ApS |
Methods for predicting drug responsiveness in cancer patients
|
|
GB201909191D0
(en)
*
|
2019-06-26 |
2019-08-07 |
Ucb Biopharma Sprl |
Therapeutic agents
|
|
IL312506A
(en)
|
2021-11-08 |
2024-07-01 |
Progentos Therapeutics Inc |
Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
|
|
WO2025085233A1
(en)
*
|
2023-10-20 |
2025-04-24 |
Ensem Therapeutics, Inc. |
Novel derivatives of quinolinones, and compositions and methods thereof
|